Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2026)

Revolution Medicines has reported Accumulated Depreciation for 8 years, with the latest figure at $32.8 million in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 31.21% year-over-year to $32.8 million in Q2 2026; TTM through Jun 2026 was $32.8 million, a 31.21% increase from a year earlier, with the FY2025 full-year figure at $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation was $32.8 million for Q2 2026 at Revolution Medicines, up from $30.7 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $32.8 million in Q2 2026, with the low at $11.6 million in Q1 2022.
• Average Accumulated Depreciation over 5 years is $20.6 million, with a median of $19.7 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation surged 35.59% in 2023, then advanced 19.86% in 2024.
• Over 5 years, Accumulated Depreciation stood at $14.5 million in 2022, then advanced by 22.12% to $17.7 million in 2023, then climbed by 23.34% to $21.8 million in 2024, then jumped by 30.66% to $28.5 million in 2025, then grew by 15.17% to $32.8 million in 2026.
• The last three Accumulated Depreciation figures came in at $32.8 million (Q2 2026), $30.7 million (Q1 2026), and $28.5 million (Q4 2025), per Business Quant data.